UBS Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
UBS Group's CPRX Position: Q3 2026 in Review
UBS Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1,453,726 shares — an estimated $45.7M sold.
UBS Group first reported a position in CPRX in Q2 2013 and held it in 38 quarters. The position peaked at $45.7M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- UBS Group reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- UBS Group sold 1,453,726 Catalyst Pharmaceutical shares in Q3 2026, an estimated $45.7M.
- UBS Group first reported a position in Catalyst Pharmaceutical in Q2 2013 and held it in 38 quarters.
- UBS Group's Catalyst Pharmaceutical position peaked at $45.7M in Q2 2026.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.